Associated Papers
A scalable approach to resolving variants of uncertain significance.
Tejura M et al.
Biorxiv : the Preprint Server for Biology, 2026
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.
Zwierenga F et al.
Targeted Oncology, 2025
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers.
Marshall CH et al.
Cancers, 2025
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Storandt MH et al.
Cancers, 2025
Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy).
Ernst MPT et al.
Hemasphere, 2025
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A et al.
Journal of Hematology & Oncology, 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis.
Naumann N et al.
Cancers, 2024
Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Porta C et al.
Lung Cancer (amsterdam, Netherlands), 2023
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.
Homan CC et al.
Blood Advances, 2023
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Toribio-Castelló S et al.
Cancers, 2023
Identification of prognostic and driver gene mutations in acute myeloid leukemia by a bioinformatics analysis.
Li L et al.
Translational Cancer Research, 2023
Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational Landscape.
Ratnasinghe BD et al.
Biorxiv : the Preprint Server for Biology, 2023
In Silico Analysis of nsSNPs of Human KRAS Gene and Protein Modeling Using Bioinformatic Tools.
Xu D et al.
Acs Omega, 2023
RASopathies and cardiac manifestations.
Hilal N et al.
Frontiers in Cardiovascular Medicine, 2023
Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscape.
Ratnasinghe BD et al.
Computational and Structural Biotechnology Journal, 2023
Acquired somatic variants in inherited myeloid malignancies.
Armes H et al.
Leukemia, 2022
KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.
Vendramini E et al.
Cancers, 2022
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts.
Dunnett-Kane V et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2020
PEDIA: prioritization of exome data by image analysis.
Hsieh TC et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2019
Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N et al.
Oncology Reports, 2019
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Wong TN et al.
Nature Communications, 2018
Long-term efficacy of recombinant human growth hormone therapy in short-statured patients with Noonan syndrome.
Jeong I et al.
Annals of Pediatric Endocrinology & Metabolism, 2016
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Patel KP et al.
Blood, 2015
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C et al.
Molecular Systems Biology, 2014
Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.
Klco JM et al.
Cancer Cell, 2014
Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.
Li C et al.
Plos One, 2014
Two novel germline KRAS mutations: expanding the molecular and clinical phenotype.
Stark Z et al.
Clinical Genetics, 2012
Characterization of a novel KRAS mutation identified in Noonan syndrome.
Razzaque MA et al.
American Journal of Medical Genetics. Part A, 2012
Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation.
Choi JH et al.
Hormone Research in Paediatrics, 2012
Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.
Lo FS et al.
European Journal of Pediatrics, 2009
An unexpected new role of mutant Ras: perturbation of human embryonic development.
Kratz CP et al.
Journal of Molecular Medicine (berlin, Germany), 2007
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.
Zenker M et al.
Journal of Medical Genetics, 2007